Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab with mFOLFOX6 in Resected Colon Cancer
NCT00096278Phase 3Completed
- Sponsor
- National Cancer Institute
- Start
- Sep 2004
- Primary completion
- Mar 2009
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of bevacizumab in colon adenocarcinoma (2 arms), sponsored by National Cancer Institute. Primary endpoint: Disease-free Survival at 3 years. Started Sep 2004; status: completed.
02
Drugs
bevacizumab
03
Conditions
colon adenocarcinoma
Beyond the preview
Go deeper on NCT00096278.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00096278.